OGT and Cartagenia Collaborate in Automated Aberration Data Transfer
Aiding confident disease diagnosis in clinical research
Oxford, UK – 09 June 2010. Oxford Gene Technology (OGT), provider of innovative clinical
genetics and diagnostic solutions to advance molecular medicine, today announced that its
CytoSure™ Interpret Software can now seamlessly transfer array comparative genomic
hybridisation (aCGH) aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics
platform. This helps cytogeneticists accurately correlate genotypic findings with known clinical
phenotypes. Further details of this new functionality will be presented in two workshops at the
European Human Genetics Conference 2010 in Gothenburg, Sweden, 12-15 June. On 12 June,
OGT will present “From disease to cytogenetics research – An integrated CNV analysis platform
from Oxford Gene Technology” at 12.00 in room H1. Following on from this at 14.00 in room R4,
Cartagenia will present “Routine clinical interpretation of copy number variation”.
With the ability to automatically detect CNV aberrations, CytoSure Interpret Software generates
reliable and reproducible results, which can be cross referenced with external aberration
databases for accurate data interpretation. These results can now be effortlessly transferred to
Cartagenia’s Bench platform, allowing additional data management options — including quick and secure data sharing within, and across, various research facilities — and support for genotypephenotype correlation analysis.
OGT and Cartagenia will be exhibiting at ESHG 2010 on booths B-550 and B-632 respectively.
More information on OGT’s CytoSure products can be found at www.ogt.co.uk/cytosure.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.